US2016115489A1PendingUtilityA1

Crispr-cas component systems, methods and compositions for sequence manipulation

Assignee: BROAD INST INCPriority: Dec 12, 2012Filed: Jan 8, 2016Published: Apr 28, 2016
Est. expiryDec 12, 2032(~6.4 yrs left)· nominal 20-yr term from priority
C12N 2310/20C12N 15/63C12N 2310/3519C12N 2310/531C12N 15/74C12N 15/85C12N 15/1082C12N 2800/101C12N 15/70C12N 9/22C12N 15/113C12N 15/8509C12N 15/907C12N 15/102C12N 15/746G16B 30/10G16B 20/50G16B 20/30G16B 20/20C12N 2320/30C12N 2320/11C12N 2310/10C12N 15/79G16B 20/00G16B 30/00C12N 2750/14143
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of inducing cell death of one or more prokaryotic cell(s) comprising:
 introducing one or more vectors into the prokaryotic cell(s);   wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence;   and all of a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence, are produced in the prokaryotic cell(s);   wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridized to a target sequence within a target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence;   wherein binding of the CRISPR complex to the target polynucleotide results in Cas9-directed cleavage at a targeted site in the prokaryote(s) and induces cell death.   
     
     
         2 . The method of  claim 1 , wherein the CRISPR enzyme is a type II CRISPR system enzyme. 
     
     
         3 . The method of  claim 1 , wherein the CRISPR enzyme is a Cas9. 
     
     
         4 . The method of  claim 3 , wherein the Cas9 is  S. pyogenes  Cas9. 
     
     
         5 . The method of  claim 1 , wherein the CRISPR enzyme is not endogenous to the prokaryote(s). 
     
     
         6 . The method of  claim 1  wherein the prokaryote(s) is  S. pneumoniae  or  E. coli.    
     
     
         7 . The method of  claim 1  wherein the one or more vectors are plasmids.

Join the waitlist — get patent alerts

Track US2016115489A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.